Journal Information
Vol. 42. Issue S2.
Pages 421-422 (November 2020)
Download PDF
More article options
Vol. 42. Issue S2.
Pages 421-422 (November 2020)
Open Access
D.M.C. Fantacinia, S.C.G. Limaa, H. Branda, L.C. Batistaa, R. Cunhab,c, D.T. Covasd, L.E.B. Souzaa
a Centro de Terapia Celular (CTC), Laboratório de Transferência Gênica, Fundação Hemocentro de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
b Centro de Terapia Celular (CTC), Advanced Cellular Therapy Laboratory, Fundação Hemocentro de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
c Department of Medical Images, Hematology, and Medical Oncology, Bone Marrow Transplantation and Cellular Therapy Unit, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
d Centro de Terapia Celular (CTC), Fundação Hemocentro de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
Article information
Full Text

Chimeric antigen receptor (CAR) T cell therapy is a new approach for treatment of cancer. Production of CAR-T cells requires several carefully performed steps and consistent production of optimal viral vectors is a critical step to ensure efficient gene modification of lymphocytes. Optimizing the production of vectors for CAR-T cell transduction before beginning large-scale manufacturing reduces variability and maximizes efficiency. Here, we demonstrated that an improvement in lentiviral production can be achieved by optimizing parameters such as serum-free media for lentivirus (LV) harvesting, PEI formulations, DNA amount, PEI:DNA ratios and producer cell lines. Initially, we evaluated the LV titers harvesting in different media: TexMACS™, X-VIVO™10, FreeStyle™ and DMEM supplemented with 10% fetal bovine serum (FBS). Our hypothesis was that collecting LV particles in a medium optimized for T-cell growth, such as TexMACS and X-VIVO 10, would improve transduction efficiencies. In addition, we included DMEM 10% FBS and FreeStyle media which are commonly used for viral production for comparison. For this purpose, HEK293/T17 cells were transfected with lipofectamine and viral titers were measured by flow cytometry. Among the media tested, harvesting in TexMACS and DMEM 10% FBS yielded the highest viral titers (4×106 transducing units per mL or TU/mL). Next, we compared the three most used DNA-delivery methods: calcium phosphate precipitation, cationic lipids (Lifofectamine™) and polycations (linear PEI 25 KDa, PEIPro and PEI JetOptimus). The resulting LV titers were compared to that obtained with lipofectamine-based transfection. The infectious titers obtained from calcium phosphate transfection method were the lowest among the tested methods. In addition, viral titers were decreased as the amount of PEI was increased. We found that among the PEI formulations, transfection with PEI JetOptimus resulted in the highest LV titers. The yields were further increased when the DNA amount was reduced to 104 ng/cm2 and the producer cell line was changed to LentiX-293T (1.32×107 ± 0.13×107 TU/mL). Viral titer resulting of lipofectamine-based transfection in the same conditions was equivalent (1.29×107 ± 1.30×106 IU/mL). Finally, we evaluated if these tested variables in producing LV particles would affect transduction efficiency. To that end, we generated CAR-T cells by transducing human T-cells with LV particles harvested in TexMACs medium after transfection with Lipofectamine (L-TEX group) or PEI JetOptimus (PJ-TEX group). LV produced by Lipofectamine transfection and harvested in DMEM 10% FBS (L-DMEM group) were used as controls. Quantification of CAR-T cells by flow cytometry demonstrated that transduction with both LV supernatants produced in serum-free medium (L-TEX and PJ-TEX) more than doubled the frequency of CAR+ cells compared to the L-DMEM condition (L-DMEM = 30.77%±0.04%, L-TEX = 76.01%±0.25%, PJ-TEX = 73.54%±1.05% CAR+cells). In addition to bringing practical solutions in the improvement of LV vector production, this work serves as a stepping stone for newcomers in the field as it highlights the critical variables needed to establish a cost-effective production process of LV vectors for research and early clinical studies on CAR-T cells. Funding: FAPESP (2013/08135-2, 2019/18672-1, 2019/18702-8 and 2020/02043-2); CNPq (465539/2014-9).

Hematology, Transfusion and Cell Therapy

Subscribe to our newsletter

Article options